These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9102483)

  • 1. Prospects for Chemoprevention in Cohorts with Cancer Risk Markers. Proceedings of a conference. Easton, Maryland, October 5-7, 1995.
    J Cell Biochem Suppl; 1996; 25():1-206. PubMed ID: 9102483
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995.
    J Cell Biochem Suppl; 1995; 23():1-250. PubMed ID: 8786651
    [No Abstract]   [Full Text] [Related]  

  • 4. International Meeting on Cancer Chemoprevention: molecular basis, mechanisms and trials.
    Bartsch H; Frank N; Gerhäuser C; Owen RW; Berger MR
    Eur J Cancer Prev; 1997 Feb; 6(1):80-92. PubMed ID: 9161817
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Chemopreventive Agents: Drug Development Status and Future Prospects. Conference proceedings. Princeton, New Jersey, October 18-22, 1994.
    J Cell Biochem Suppl; 1995; 22():1-262. PubMed ID: 8538184
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for identification and clinical evaluation of promising chemopreventive agents.
    Kelloff GJ; Hawk ET; Crowell JA; Boone CW; Nayfield SG; Perloff M; Steele VE; Lubet RA
    Oncology (Williston Park); 1996 Oct; 10(10):1471-84; discussion 1484-8. PubMed ID: 8905841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic oxidative stress and cancer: mechanisms, biomarkers and prevention. Proceedings of an international conference. October 23-26, 2005. Heidelberg, Germany.
    Biol Chem; 2006 Apr; 387(4):347-483. PubMed ID: 16606330
    [No Abstract]   [Full Text] [Related]  

  • 10. Chemoprevention of Breast Cancer: Surrogate Endpoints and Agents in Short-Term Clinical Trials. Proceedings of a workshop. Lake Tahoe, California, October 6-10, 1993.
    J Cell Biochem Suppl; 1993; 17G():1-263. PubMed ID: 7911859
    [No Abstract]   [Full Text] [Related]  

  • 11. Biological monitoring of cancer chemoprevention.
    Pillai R; Garewal HS; Wood S; Watson RR
    J Surg Oncol; 1992 Nov; 51(3):195-202. PubMed ID: 1434646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of cancer.
    Sporn MB
    Lancet; 1993 Nov; 342(8881):1211-3. PubMed ID: 7901533
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis.
    Kim HS; Kacew S; Lee BM
    Arch Toxicol; 2016 Oct; 90(10):2389-404. PubMed ID: 27538406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.
    Monteiro de Oliveira Novaes JA; William WN
    Future Oncol; 2016 Oct; 12(20):2379-86. PubMed ID: 27329013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proceedings of the conference Vitamin D and Cancer: Current Dilemmas and Future Needs, Bethesda, Maryland, USA, May 7-8, 2007.
    Nutr Rev; 2007 Aug; 65(8 Pt 2):S71-137. PubMed ID: 17933025
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular epidemiologic methods in cancer chemoprevention.
    Perera FP; Blaner W; Mooney LV
    Eur J Cancer Prev; 1996 Dec; 5 Suppl 2():19-25. PubMed ID: 9061290
    [No Abstract]   [Full Text] [Related]  

  • 17. Biomarkers as intermediate end points in chemoprevention trials.
    Lippman SM; Lee JS; Lotan R; Hittelman W; Wargovich MJ; Hong WK
    J Natl Cancer Inst; 1990 Apr; 82(7):555-60. PubMed ID: 2179569
    [No Abstract]   [Full Text] [Related]  

  • 18. The use and misuse of biomarkers as indicators of cancer risk reduction following dietary manipulation. Proceedings of a conference. July 12-13, 2006. Bethesda, Maryland, USA.
    J Nutr; 2006 Oct; 136(10):2666S-713S. PubMed ID: 17068853
    [No Abstract]   [Full Text] [Related]  

  • 19. The place of chemoprevention studies in cancer prevention planning.
    Meyskens FL
    Prog Clin Biol Res; 1990; 346():135-43. PubMed ID: 2197622
    [No Abstract]   [Full Text] [Related]  

  • 20. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.